These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33422245)

  • 1. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Kimathi D; Juan-Giner A; Orindi B; Grantz KH; Bob NS; Cheruiyot S; Hamaluba M; Kamau N; Fall G; Dia M; Mosobo M; Moki F; Kiogora K; Chirro O; Thiong'o A; Mwendwa J; Guantai A; Karanja HK; Gitonga J; Mugo D; Ramko K; Faye O; Sanders EJ; Grais RF; Bejon P; Warimwe GM
    Lancet Infect Dis; 2023 Aug; 23(8):974-982. PubMed ID: 37127045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Juan-Giner A; Namulwana ML; Kimathi D; Grantz KH; Fall G; Dia M; Bob NS; Sall AA; Nerima C; Sahani MK; Mulogo EM; Ampeire I; Hombach J; Nanjebe D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet Infect Dis; 2023 Aug; 23(8):965-973. PubMed ID: 37127047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
    Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
    N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
    Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
    Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.
    Casey RM; Najjengo MS; Lubega I; Sekiziyivu AB; Twinomuhwezi-Oyet E; Nakato WN; Sciarratta CN; Chu SY; Doshi RH; Kambugu A; Gidudu JF
    Vaccine; 2024 Sep; 42(22):126197. PubMed ID: 39153293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
    Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
    Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Song KR; Chapagain RH; Tamrakar D; Shrestha R; Kanodia P; Chaudhary S; Wartel TA; Yang JS; Kim DR; Lee J; Park EL; Cho H; Lee J; Thaisrivichai P; Vemula S; Kim BM; Gupta B; Saluja T; Pansuriya RK; Ganapathy R; Baik YO; Lee YJ; Jeon S; Park Y; Her HL; Park Y; Lynch JA
    Lancet Glob Health; 2024 May; 12(5):e826-e837. PubMed ID: 38614631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis.
    Nnaji CA; Shey MS; Adetokunboh OO; Wiysonge CS
    Vaccine; 2020 Feb; 38(6):1291-1301. PubMed ID: 31859201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.
    Martins RM; Maia Mde L; Farias RH; Camacho LA; Freire MS; Galler R; Yamamura AM; Almeida LF; Lima SM; Nogueira RM; Sá GR; Hokama DA; de Carvalho R; Freire RA; Pereira Filho E; Leal Mda L; Homma A
    Hum Vaccin Immunother; 2013 Apr; 9(4):879-88. PubMed ID: 23364472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
    Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
    Tonacio AC; do Nascimento Pedrosa T; Borba EF; Aikawa NE; Pasoto SG; Filho JCRF; Sampaio Barros MM; Leon EP; Lombardi SCFS; Junior AM; Azevedo AS; Schwarcz WD; Fuller R; Yuki EFN; Ugolini Lopes MR; Rodrigues Pereira RM; Sampaio Barros PD; de Andrade DCO; de Medeiros-Ribeiro AC; de Moraes JCB; Shinjo SK; Miossi R; da Silva Duarte AJ; Lopes MH; Kallás EG; Almeida da Silva CA; Bonfá E
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0010002. PubMed ID: 34843469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.